• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Extended-Release Guanfacine Improves ADHD Symptoms in Autism

Extended-Release Guanfacine Improves ADHD Symptoms in Autism

July 1, 2016
Bret A. Moore, PsyD, ABPP
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Bret A. Moore, PsyD, ABPP. Board-Certified Clinical Psychologist, San Antonio, TX. Dr. Moore has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Subject:
(Scahill S et al, Am J Psychiatry 2016;172:1197–1206)

Short Description:

Children with autism spectrum disorder (ASD) often have symptoms of ADHD. While it’s not always easy to distinguish them from the core features of autism, symptoms such as impulsivity, hyperactivity, and distractibility do occur, and we often use medications to target them. Stimulants are fairly effective but tend to cause more side effects in autistic ADHD kids than in children with pure ADHD. Atomoxetine was only equivocally effective in one trial, and the immediate-release version of guanfacine was tested in a small open-label trial, resulting in improvement in about half the subjects.

Recognizing the need for more data, researchers conducted the first ever randomized placebo-controlled trial of guanfacine in ASD/ADHD, in this case using the extended-release (ER) version. Children between the ages of 5 and 14 with a diagnosis of ASD with accompanying impulsivity, hyperactivity, and distractibility were randomly assigned to either ER guanfacine (n = 30) or placebo (n = 32). During this 8-week trial, ER guanfacine was started at 1 mg once a day for all children. Depending on the child’s weight and response, a maximum of 4 mg daily could be prescribed. The primary outcome measure was change from baseline on the parent version of the Aberrant Behavior Checklist (ABC) hyperactivity subscale, which was assessed at weeks 4, 6, and 8. The Clinical Global Impression-Improvement (CGI-I) scale was also used.

ER guanfacine was effective. At the end of 8 weeks, the medication group showed a 44% reduction in scores on the ABC hyperactivity subscale compared to 13% for the placebo group. For the ER guanfacine group, half were rated “much improved” or “very much improved” on the CGI-I, whereas fewer than 10% of the placebo group were so rated. Significant improvements were seen in both hyperactivity and inattention vs. placebo. The most frequently prescribed dose in both groups was 3 mg. Overall, ER guanfacine was well tolerated. The most common complaints were drowsiness, fatigue, and loss of appetite. Drops in blood pressure and heart rate from baseline were seen in the guanfacine group. Blood pressure normalized by the end of 8 weeks, but heart rate did not, remaining about 10 points below baseline. This effect was not considered clinically significant.

CCPR’s Take: This was a small study of short duration, but the results were promising. When using ER guanfacine, start with 1 mg in the morning and titrate up slowly as needed. Dose it in the evening if the child becomes drowsy. By the way, ER guanfacine is now available as a cheap generic, so don’t feel guilty prescribing it. On the other hand, the ER version’s duration of action is only marginally longer than the IR version (about 24 hours vs. about 17 hours) so you don’t gain much by choosing it.

Child Psychiatry
KEYWORDS autism-spectrum-disorder child-psychiatry psychopharmacology_tips
    Bret a moore psyd abpp
    Bret A. Moore, PsyD, ABPP

    Good News for Smoking Cessation Drugs: Not as Scary as Once Thought

    More from this author
    www.thecarlatreport.com
    Issue Date: July 1, 2016
    SUBSCRIBE NOW
    Table Of Contents
    Treating Disruptive Behavior Disorders in Children
    Evolution of Childhood Bipolar Disorder in the United States
    Atomoxetine Does Not Increase Risk of Suicide Compared to Stimulants
    Extended-Release Guanfacine Improves ADHD Symptoms in Autism
    Disruptive Mood Dysregulation Disorder: A Primer
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.